MX2025001020A - Compuesto de anillo fusionado, metodo de preparacion del mismo y su aplicacion medicinal - Google Patents
Compuesto de anillo fusionado, metodo de preparacion del mismo y su aplicacion medicinalInfo
- Publication number
- MX2025001020A MX2025001020A MX2025001020A MX2025001020A MX2025001020A MX 2025001020 A MX2025001020 A MX 2025001020A MX 2025001020 A MX2025001020 A MX 2025001020A MX 2025001020 A MX2025001020 A MX 2025001020A MX 2025001020 A MX2025001020 A MX 2025001020A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- fused ring
- method therefor
- ring compound
- medicinal application
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente invención se refiere a un compuesto de anillo fusionado, un método de preparación para el mismo y una aplicación medicinal del mismo. Específicamente, la presente invención se refiere a un compuesto de anillo fusionado representado por la fórmula general (IN), un método de preparación para el mismo, una composición farmacéutica que contiene el compuesto y un uso del mismo como agente terapéutico, en particular, el uso del mismo en la preparación de un fármaco para inhibir KRAS G12D. Cada grupo en la fórmula general (IN) es como se define en la descripción. (ver Fórmula).
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210891331 | 2022-07-27 | ||
| CN202211467809 | 2022-11-22 | ||
| CN202211724856 | 2022-12-27 | ||
| CN202211724115 | 2022-12-30 | ||
| CN202310120312 | 2023-02-15 | ||
| CN202310234194 | 2023-03-10 | ||
| CN202310676437 | 2023-06-08 | ||
| PCT/CN2023/109598 WO2024022444A1 (zh) | 2022-07-27 | 2023-07-27 | 稠环类化合物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025001020A true MX2025001020A (es) | 2025-03-07 |
Family
ID=89705453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025001020A MX2025001020A (es) | 2022-07-27 | 2025-01-24 | Compuesto de anillo fusionado, metodo de preparacion del mismo y su aplicacion medicinal |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4563580A4 (es) |
| JP (1) | JP2025524846A (es) |
| KR (1) | KR20250042155A (es) |
| CN (1) | CN119365465A (es) |
| CA (1) | CA3261072A1 (es) |
| MX (1) | MX2025001020A (es) |
| TW (1) | TW202409051A (es) |
| WO (1) | WO2024022444A1 (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| CN119365467A (zh) | 2022-05-19 | 2025-01-24 | 基因泰克公司 | 氮杂-四环氧氮杂䓬化合物及其用途 |
| AU2023320565A1 (en) | 2022-08-05 | 2025-01-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| AU2023396551A1 (en) * | 2022-12-15 | 2025-06-12 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Pyrimidine-containing polycyclic derivative inhibitor, and preparation method therefor and use thereof |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| WO2024208305A1 (zh) * | 2023-04-07 | 2024-10-10 | 江苏恒瑞医药股份有限公司 | 稠合四环类化合物、其制备方法及其在医药上的应用 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| WO2025006967A1 (en) | 2023-06-30 | 2025-01-02 | Bristol-Myers Squibb Company | Kras inhibitors |
| CN121843945A (zh) * | 2023-07-18 | 2026-04-10 | 泰励生物科技(上海)有限公司 | 具有抗kras突变肿瘤活性的化合物 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| WO2025045141A1 (en) * | 2023-08-31 | 2025-03-06 | Suzhou Zanrong Pharma Limited | Kras inhibitors and uses thereof |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025108443A2 (en) * | 2023-11-23 | 2025-05-30 | Beigene Switzerland Gmbh | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| AU2025209726A1 (en) * | 2024-01-17 | 2026-07-09 | Suzhou Zanrong Pharma Limited | Kras inhibitors and uses thereof |
| TW202535411A (zh) * | 2024-01-24 | 2025-09-16 | 大陸商上海翰森生物醫藥科技有限公司 | 嘧啶多環類衍生物抑制劑、其製備方法和應用 |
| WO2025157260A1 (zh) * | 2024-01-26 | 2025-07-31 | 江苏恒瑞医药股份有限公司 | G12d抑制剂化合物的可药用盐及其晶型 |
| CN119490512B (zh) * | 2024-01-26 | 2026-06-16 | 苏州盛迪亚生物医药有限公司 | 一种苯并噻吩取代稠环化合物的可药用盐、其结晶形式及用途 |
| CN119661555B (zh) * | 2024-01-26 | 2026-04-14 | 苏州盛迪亚生物医药有限公司 | 一种稠环类化合物的可药用盐、其结晶形式及用途 |
| WO2025157261A1 (zh) * | 2024-01-26 | 2025-07-31 | 江苏恒瑞医药股份有限公司 | G12d抑制剂化合物晶型及其制备方法 |
| CN119684315B (zh) * | 2024-01-26 | 2026-05-12 | 苏州盛迪亚生物医药有限公司 | 一种苯并噻吩取代稠环化合物的结晶形式及其制备方法 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025256655A1 (zh) * | 2024-06-14 | 2025-12-18 | 上海翰森生物医药科技有限公司 | 一种含嘧啶多元并环类衍生物抑制剂的晶型及其制备方法 |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026073024A1 (en) * | 2024-09-30 | 2026-04-02 | Gilead Sciences, Inc. | Kras g12d inhibitors for the treatment of cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026098684A1 (zh) * | 2024-11-11 | 2026-05-15 | 上海科州药物股份有限公司 | 作为kras抑制剂的杂环化合物,及其制备和治疗用途 |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2875242B1 (fr) | 2004-09-10 | 2006-11-17 | Biomerieux Sa | Nouveaux substrats enzymatiques derives de phenoxazinone et leur utilisation comme revelateur dans la detection de microorganismes a activite peptidase |
| ES2924698T3 (es) | 2015-05-28 | 2022-10-10 | Theravance Biopharma R&D Ip Llc | Proceso e intermedios para la preparación de compuestos de naftiridina como inhibidores de quinasa JAK |
| WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| CN112119075B (zh) | 2018-08-16 | 2024-03-12 | 豪夫迈·罗氏有限公司 | 稠环化合物 |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| CN113874374B (zh) | 2019-05-24 | 2024-12-27 | 江苏恒瑞医药股份有限公司 | 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| WO2021000885A1 (zh) | 2019-07-01 | 2021-01-07 | 江苏恒瑞医药股份有限公司 | 喹唑啉酮类衍生物、其制备方法及其在医药上的应用 |
| CN114615981B (zh) * | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| CR20220258A (es) | 2019-12-11 | 2022-07-03 | Lilly Co Eli | Inhibidores de kras g12c |
| GB202011996D0 (en) | 2020-07-31 | 2020-09-16 | Adorx Therapeutics Ltd | Antagonist compounds |
| EP4204412A4 (en) | 2020-08-26 | 2024-10-09 | InventisBio Co., Ltd. | HETEROARYL COMPOUNDS, PRODUCTION PROCESSES AND USES THEREOF |
| WO2022148422A1 (en) | 2021-01-08 | 2022-07-14 | Beigene, Ltd. | Bridged compounds as kras g12d inhibitor and degrader and the use thereof |
| CN116867792A (zh) | 2021-02-09 | 2023-10-10 | 基因泰克公司 | 四环氧氮杂䓬化合物及其用途 |
| US20240199644A1 (en) * | 2021-03-07 | 2024-06-20 | Jacobio Pharmaceuticals Co., Ltd. | Fused Ring Derivatives Useful as KRAS G12D Inhibitors |
| CN117043167A (zh) * | 2021-03-17 | 2023-11-10 | 劲方医药科技(上海)有限公司 | 嘧啶并环类化合物及其制法和用途 |
| CN117083281A (zh) * | 2021-03-24 | 2023-11-17 | 南京明德新药研发有限公司 | 嘧啶并杂环类化合物及其应用 |
| WO2022206723A1 (zh) * | 2021-03-30 | 2022-10-06 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| WO2022232331A1 (en) | 2021-04-29 | 2022-11-03 | Amgen Inc. | Heterocyclic compounds and methods of use |
| WO2022247757A1 (zh) | 2021-05-26 | 2022-12-01 | 南京明德新药研发有限公司 | 氟取代的嘧啶并吡啶类化合物及其应用 |
| MX2023015533A (es) * | 2021-06-21 | 2024-01-23 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina. |
| CN115557974A (zh) | 2021-07-02 | 2023-01-03 | 上海迪诺医药科技有限公司 | Kras g12d抑制剂及其应用 |
| CN117677624A (zh) * | 2021-07-19 | 2024-03-08 | 上海艾力斯医药科技股份有限公司 | 新型吡啶并嘧啶衍生物 |
| CA3226720A1 (en) * | 2021-07-23 | 2023-01-26 | Suzhou Zanrong Pharma Limited | Kras g12d inhibitors and uses thereof |
| WO2023025116A1 (zh) * | 2021-08-25 | 2023-03-02 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| TW202315626A (zh) | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| WO2023103906A1 (zh) * | 2021-12-07 | 2023-06-15 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| EP4511127A1 (en) * | 2022-04-21 | 2025-02-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| CN119365467A (zh) * | 2022-05-19 | 2025-01-24 | 基因泰克公司 | 氮杂-四环氧氮杂䓬化合物及其用途 |
-
2023
- 2023-07-27 TW TW112128178A patent/TW202409051A/zh unknown
- 2023-07-27 CN CN202380046968.5A patent/CN119365465A/zh active Pending
- 2023-07-27 JP JP2025502591A patent/JP2025524846A/ja active Pending
- 2023-07-27 WO PCT/CN2023/109598 patent/WO2024022444A1/zh not_active Ceased
- 2023-07-27 KR KR1020257005109A patent/KR20250042155A/ko active Pending
- 2023-07-27 CA CA3261072A patent/CA3261072A1/en active Pending
- 2023-07-27 EP EP23845651.1A patent/EP4563580A4/en active Pending
-
2025
- 2025-01-24 MX MX2025001020A patent/MX2025001020A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4563580A4 (en) | 2025-10-29 |
| JP2025524846A (ja) | 2025-08-01 |
| EP4563580A1 (en) | 2025-06-04 |
| CN119365465A (zh) | 2025-01-24 |
| CA3261072A1 (en) | 2025-04-07 |
| WO2024022444A1 (zh) | 2024-02-01 |
| TW202409051A (zh) | 2024-03-01 |
| KR20250042155A (ko) | 2025-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023015533A (es) | Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina. | |
| MX2025001619A (es) | Inhibidor de pde4b y uso del mismo | |
| MX2025001700A (es) | Compuestos triciclicos y uso medico de los mismos | |
| MX2023012361A (es) | Inhibidor de parp que contiene estructura de piperazina, metodo de preparacion del mismo y uso farmaceutico del mismo. | |
| MX2022013054A (es) | Derivados de imidazolidinona y uso medico de los mismos. | |
| MX2025000291A (es) | Compuesto heterocíclico capaz de inhibir prmt5mta y uso del mismo | |
| MX2023013890A (es) | Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos. | |
| CR20240160A (es) | Compuestos espirocíclicos | |
| MX2023006193A (es) | Compuesto triciclico fusionado, metodo de preparacion y aplicacion del mismo en medicina. | |
| TW200503775A (en) | Pharmaceutical composition and method for treating | |
| MX2023003576A (es) | Compuesto como inhibidor de la akt cinasa. | |
| ZA202501471B (en) | Preparation and use of quinazolinone derivative as kinase inhibitor | |
| ZA202400988B (en) | Aak1 inhibitor and use thereof | |
| MX2022015554A (es) | Moduladores de molecula peque?a de interleucina 17 (il-17). | |
| MX2026001837A (es) | Compuestos que contienen ciclobutilo | |
| MX2024011705A (es) | Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica | |
| MX2025013245A (es) | Compuesto de camptotecina deuterado, preparacion y uso de este | |
| MX2023005086A (es) | Compuestos de pirimidina, composiciones y aplicaciones medicas de esta. | |
| MX2024014315A (es) | Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas | |
| MX2023005078A (es) | Nuevas formas cristalinas de un compuesto inhibidor de kras g12c. | |
| MX2025009374A (es) | Compuesto que contiene trifluorometilsulfonilo | |
| CA3136727A1 (en) | Methods of administering an arip-iprazole injectable preparation | |
| MX2024000999A (es) | Antagonista de molécula pequeña de lpa1. | |
| MX2025005318A (es) | Compuesto de cucurbiturilo y uso medico del mismo | |
| GB2590189A9 (en) | Lycorine derivatives, pharmaceutical composite thereof and usage therefor |